Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | CNR1 | P21554 | 1/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095203 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL15276769 | 0.99 | ALDH1A1 (0.97) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL15276802 | 0.93 | ALDH1A1 (0.86) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL7821199 | 0.91 | SMN1; SMN2 (0.84) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL28912823 | 0.90 | ALDH1A1 (0.82) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL1119369 | 0.90 | ALDH1A1 (0.82) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL1001319 | 0.90 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL13532150 | 0.89 | SIRT2 (0.81) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL1001675 | 0.89 | L3MBTL1 (0.83) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL14291958 | 0.89 | ALDH1A1 (0.80) | ALDH1A1SMN1; SMN2GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129834-B2 | Combinations and methods comprising a capsid assembly inhibitor | NOVIRA THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10441589-B2 | Combinations and methods comprising a capsid assembly inhibitor | NOVIRA THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20170340642-A1 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2017-11-30 | — | — | US | disclosed |
| US-20170340642-A1 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2017-11-30 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170182021-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150216938-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140179665-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | ALDH1A1 188/4885SMN1; SMN2 965/4885GAA 607/4885 |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
| US-20150216938-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | IFNAR1, IFNG, HDGF | ALDH1A1 2345/4885SMN1; SMN2 4485/4885GAA 800/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
| US-11129834-B2 | Combinations and methods comprising a capsid assembly inhibitor | HAVCR2, HCCS, COPB1 | ALDH1A1 4289/4885SMN1; SMN2 3331/4885GAA 710/4885 |
| US-20140179665-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
| US-20170340642-A1 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | HAVCR2, HCCS, COPB1 | ALDH1A1 4289/4885SMN1; SMN2 3331/4885GAA 710/4885 |
| US-10441589-B2 | Combinations and methods comprising a capsid assembly inhibitor | HAVCR2, HCCS, COPB1 | ALDH1A1 4289/4885SMN1; SMN2 3331/4885GAA 710/4885 |
| US-20170182021-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | IFNAR1, IFNG, HDGF | ALDH1A1 2345/4885SMN1; SMN2 4485/4885GAA 800/4885 |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | ALDH1A1 1564/4885SMN1; SMN2 4356/4885GAA 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.